Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults.

@article{DIgnazio2005NovelSM,
  title={Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults.},
  author={Joseph D'Ignazio and Marco A Camere and Drew E Lewis and Daniel M Jorgensen and Jeanne D. Breen},
  journal={Antimicrobial agents and chemotherapy},
  year={2005},
  volume={49 10},
  pages={
          4035-41
        }
}
This randomized, double-blind, noninferiority study was designed to demonstrate that a single 2.0-g oral dose of a novel microsphere formulation of azithromycin was at least as effective as 7 days of levofloxacin, 500 mg/day, in the treatment of adult patients with mild to moderate community-acquired pneumonia (Fine classes I, II, and III). In total, 427 subjects were randomly assigned to receive either a single 2.0-g dose of azithromycin microspheres (n = 213) or a 7-day regimen of… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 30 CITATIONS

Clinical applications of azithromycin microspheres in respiratory tract infections

  • International journal of nanomedicine
  • 2007
VIEW 7 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED